Literature DB >> 12711162

Interactions of amphiphilic calix[4]arene-based Solid Lipid Nanoparticles with bovine serum albumin.

Jérôme Gualbert1, Patrick Shahgaldian, Anthony W Coleman.   

Abstract

The interaction of Solid Lipid Nanoparticles (SLN) based on amphiphilic calix[4]arene with one of the major circulatory protein, serum albumin, has been investigated by Photon Correlation Spectroscopy (PCS) and Atomic Force Microscopy (AFM). The carrier systems have shown the ability to interact with bovine serum albumin (BSA), which forms a capping layer up to 17nm in depth. AFM imaging revealed that the SLNs are protected by this layer against flattening on surfaces.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12711162     DOI: 10.1016/s0378-5173(03)00138-8

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Supramolecular interaction of two tryptophans with p-sulfonated calix[4,6,8]arene.

Authors:  Tao-Tao Pang; Hai-Long Liu; Li-Ming Du; Yin-Xia Chang; Yun-Long Fu
Journal:  J Fluoresc       Date:  2013-07-31       Impact factor: 2.217

Review 2.  Lipid-based colloidal carriers for peptide and protein delivery--liposomes versus lipid nanoparticles.

Authors:  Susana Martins; Bruno Sarmento; Domingos C Ferreira; Eliana B Souto
Journal:  Int J Nanomedicine       Date:  2007

Review 3.  Solid lipid nanoparticle-based calix[n]arenes and calix-resorcinarenes as building blocks: synthesis, formulation and characterization.

Authors:  Imed Montasser; Patrick Shahgaldian; Florent Perret; Anthony W Coleman
Journal:  Int J Mol Sci       Date:  2013-11-05       Impact factor: 5.923

4.  Stealth and Cationic Nanoliposomes as Drug Delivery Systems to Increase Andrographolide BBB Permeability.

Authors:  Vieri Piazzini; Elisa Landucci; Giulia Graverini; Domenico E Pellegrini-Giampietro; Anna Rita Bilia; Maria Camilla Bergonzi
Journal:  Pharmaceutics       Date:  2018-08-13       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.